Antiglaucoma Drugs Global Market Report 2024

“Antiglaucoma Drugs Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antiglaucoma drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antiglaucoma drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The antiglaucoma drugs market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Hospital Prescription drugs; Over-the counter drugs
• 2) By Product Type: Alpha Agonist; Beta Blockers; Prostaglandin Analogs; Combined Medication; Other Types
• 3) By Disease Condition Type: Open-Angle Glaucoma; Angle-Closure Glaucoma; Normal-Tension Glaucoma; Congenital Glaucoma; Other Types Of Glaucoma
• Companies Mentioned: Aerie Pharmaceuticals Inc.; Allergan Inc.; Novartis AG; Abbott Healthcare Pvt. Ltd.; Johnson & Johnson
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Antiglaucoma drugs are medications employed in the treatment and prevention of glaucoma, a vision-related condition characterized by progressive, irreversible optic nerve damage leading to vision loss.

The primary categories of antiglaucoma drugs include alpha agonists, beta-blockers, prostaglandin analogs, combined medications, and other related products. Alpha-adrenergic agonists are a class of sympathomimetic drugs that selectively activate alpha-adrenergic receptors. These antiglaucoma products are available through both hospital prescriptions and over-the-counter channels and are utilized to manage various types of glaucoma, including open-angle glaucoma, angle-closure glaucoma, normal-tension glaucoma, congenital glaucoma, and other forms of the condition.

The antiglaucoma drug market research report is one of a series of new reports from The Business Research Company that provides antiglaucoma drug market statistics, including antiglaucoma drug industry global market size, regional shares, competitors with an antiglaucoma drug market share, detailed antiglaucoma drug market segments, market trends and opportunities, and any further data you may need to thrive in the antiglaucoma drug industry. This antiglaucoma drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antiglaucoma drugs market size has grown strongly in recent years. It will grow from $15.07 billion in 2023 to $16.27 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The growth observed during the historical period can be attributed to several key factors, including the aging population, rising awareness about glaucoma, increasing healthcare expenditure, and regulatory approvals for antiglaucoma drugs. These factors have collectively contributed to the expansion of the antiglaucoma drug market.

The antiglaucoma drugs market size is expected to see strong growth in the next few years. It will grow to $21.9 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. In the forecast period, the antiglaucoma drugs market is expected to grow due to emerging markets, reimbursement policies, and disease awareness campaigns. Major trends include technological advancements, innovation, telemedicine, biologics, sustained-release formulations, and sustainability.

The incidence of glaucoma tends to increase with age, and as the global population ages, governments around the world are launching initiatives to raise awareness about glaucoma and other eye disorders. An example of such an initiative is the Vision Health program initiated by the Centers for Disease Control and Prevention (CDC) in the United States, which focuses on preventing eye disorders, including glaucoma, and improving overall eye health. Furthermore, in July 2021, the United Nations General Assembly passed a resolution emphasizing the need to expand eye care services within universal health coverage. The resolution aimed to address the adverse impacts of vision loss on sustainable development, particularly due to conditions like short and farsightedness, glaucoma, and cataracts. These government initiatives are expected to increase awareness among the public about glaucoma, which, in turn, will drive the market for antiglaucoma drugs.

The rising prevalence of myopia is expected to drive the growth of the antiglaucoma drugs market in the future. Myopia is a refractive eye condition characterized by clear vision of nearby objects but difficulty focusing on distant objects. Antiglaucoma drugs have proven to be an effective therapy for managing myopia progression and refractive regression in patients, reducing the need for ophthalmic surgeries. For instance, in December 2022, as reported by NVISION Eye Centers, a US-based medical practice company specializing in eye care, approximately 34 million people in the United States were expected to have myopia in 2022. Furthermore, a May 2022 report from the Brien Holden Vision Institute, an Austria-based nonprofit organization, projected that by 2050, half of the global population will experience myopia, with an estimated 5 billion individuals suffering from preventable vision loss. As a result, the increasing prevalence of myopia is a significant driver of growth in the antiglaucoma drugs market.

Anti-glaucoma drugs are confronted with the risk of patent expirations in the United States and Europe. Notably, medications such as travoprost and bimatoprost, commonly used for treating glaucoma, have lost their patent protection in 2021. Consequently, this has led to the introduction of generic versions of these drugs, which are typically priced lower than their branded counterparts. The availability of lower-priced generic alternatives poses a challenge to the overall growth of the antiglaucoma drug market, as it can lead to increased competition and potential revenue reductions for branded products.

Companies in the antiglaucoma drugs market are actively developing combination therapies for the treatment of glaucoma, as these therapies have shown the ability to effectively lower intraocular pressure in glaucoma patients. Many of these combination therapies are formulated as fixed-dose drugs, offering patients the convenience of consuming multiple active ingredients in a single formulation. For instance, Alcon introduced Simbrinza, a fixed combination drug that combines Brinzolamide and Brimonidine. This product is designed to help patients reduce the need for multiple individual drugs in the treatment of glaucoma. Other examples include Rockland, a combination of a rho kinase inhibitor and a prostaglandin analog, Combigan, which combines beta blockers and alpha agonists, and Cosopt, a combination of beta-blockers and carbonic anhydrase inhibitors. These combination therapies provide glaucoma patients with effective treatment options that streamline their medication regimens.

Major companies in the antiglaucoma drug market are dedicated to innovation, developing new products to better serve their customers. One such innovative product is OMLONTI (Omidenepag Isopropyl Ophthalmic Solution), which is administered as an antiglaucoma eye drop treatment, particularly effective for open-angle glaucoma. For instance, in September 2022, Santen Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, collaborated with UBE Corporation, a Japan-based chemical company, to launch OMLONTI (Omidenepag Isopropyl Ophthalmic Solution), which received approval from the US Food and Drug Administration (FDA). OMLONTI is in the form of eye drops and is employed for reducing elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. It is unique in its pharmacological action, as it is a selective prostaglandin EP2 receptor agonist, making it the only product with this distinct mechanism of action in the market. This kind of innovation demonstrates the commitment of these companies to delivering improved treatment options in the antiglaucoma drug market.

To obtain approval from the United States Food and Drug Administration (USFDA) for an antiglaucoma drug, the drug needs to demonstrate comparable intraocular pressure (IOP) lowering efficacy and a favorable benefit-to-risk ratio in comparison to established benchmark drugs used for the treatment of glaucoma. An example of such an approval is Rhopressa (netarsudil) Ophthalmic Solution, developed by Aerie Pharmaceuticals Inc. This drug received US FDA approval based on its ability to effectively lower IOP when compared to the benchmarked drugs already available for the treatment of glaucoma in the market. This stringent evaluation ensures that new antiglaucoma drugs meet the required standards for safety and efficacy.

Major companies operating in the antiglaucoma drugs market include Aerie Pharmaceuticals Inc., Allergan Inc., Novartis AG, Abbott Healthcare Pvt. Ltd., Johnson & Johnson, Merck & Co., Genentech Inc., Pfizer Inc., Bayer AG, Santen Pharmaceuticals Company Ltd., Regeneron Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., F. Hoffmann-La Roche Ltd., Hoya Corporation, Bausch + Lomb Inc., Fera Pharmaceuticals LLC, Thea Pharma Inc., Alcon AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Akorn Inc., Mylan Pharmaceuticals Pvt. Ltd., Apotex Inc., Lupin Pharmaceuticals Inc., Wockhardt Ltd., Zydus Pharmaceuticals Inc., Cooper Laboratories Inc., Cooper Pharma Ltd., Rafarm SA, Altaire Pharmaceuticals Inc.

North America was the largest region in the antiglaucoma drugs market in 2023. Middle East is expected to be the fastest-growing region in the antiglaucoma drugs market during the forecast period. The regions covered in the antiglaucoma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the antiglaucoma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The antiglaucoma drug market consists of sales of dipivefrin, epinephrine, and apraclonidine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.